Fresenius enters Schuldschein market on hunt for euros

medical right size
By Silas Brown
15 Aug 2019

German healthcare company Fresenius has launched a Schuldschein across three tenors.

Baa3/BBB/BBB- rated Fresenius has mandated LBBW and Raiffeisen Bank International to arrange the transaction, offering investors an opportunity to participate at four, seven and 10 years. Pricing margins are 55bp-70bp, 85bp-100bp and 110bp-125bp consecutively.

The initial target is €300m though that could rise if there is enough investor ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.